2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2015, 33: 1902-1909. PMID: 25847936, PMCID: PMC4451173, DOI: 10.1200/jco.2014.57.6660.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCisplatinClass I Phosphatidylinositol 3-KinasesDrug Administration ScheduleFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenomic InstabilityHeterozygoteHumansLoss of HeterozygosityMiddle AgedMutationNeoplasm StagingPhosphatidylinositol 3-KinasesTreatment OutcomeTriple Negative Breast NeoplasmsConceptsMetastatic triple-negative breast cancerGermline BRCA1/2 mutationsPhase II clinical trialTriple-negative breast cancerBRCA1/2 mutationsResponse rateClinical trialsBreast cancerMulticenter phase II clinical trialEnd pointSingle-arm phase II clinical trialCoprimary end pointsExploratory end pointsObjective response ratePIK3CA mutation statusSingle-agent platinumLong-term respondersPlatinum-based chemotherapyIdentification of patientsBRCA1/2 mutation carriersGenomic instability signatureGene expression subtypesP73 gene expressionPlatinum monotherapyMutation carriers
2000
Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States
Miron A, Schildkraut J, Rimer B, Winer E, Skinner C, Futreal P, Culler D, Calingaert B, Clark S, Marcom P, Iglehart J. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States. Annals Of Surgery 2000, 231: 624-634. PMID: 10767783, PMCID: PMC1421049, DOI: 10.1097/00000658-200005000-00002.Peer-Reviewed Original ResearchConceptsProphylactic surgeryPreventive surgeryOvarian cancerFree genetic testingProspective clinical trialsBreast cancer patientsHereditary breast cancerPositive test resultsUncertain clinical significanceMore heterogeneous populationsBaseline characteristicsCancer patientsBaseline questionnaireClinical trialsTime of entryBreast cancerClinical significanceHeterogeneous syndromeSurgeryHereditary breastNumber of womenDeleterious gene mutationsBRCA2 genesGenetic testingSpecial populations
1998
Overestimation of Hereditary Breast Cancer Risk
Iglehart J, Miron A, Rimer B, Winer E, Berry D, Shildkraut J. Overestimation of Hereditary Breast Cancer Risk. Annals Of Surgery 1998, 228: 375-384. PMID: 9742920, PMCID: PMC1191495, DOI: 10.1097/00000658-199809000-00010.Peer-Reviewed Original ResearchConceptsOvarian cancerHereditary factorsBRCA2 mutationsHereditary breast cancer riskIntensive clinical servicesTest-negative womenExpert panelBreast cancer riskCarrier probabilitiesAffected womenFamily historyCancer riskHereditary riskCancerClinical servicesBreastWomenHigher risk perceptionPretest educationWomen's perceptionsPersonal historyRiskBRCA1Disease-associated mutationsBRCA2
1997
Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History
Berry D, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History. Journal Of The National Cancer Institute 1997, 89: 227-237. PMID: 9017003, DOI: 10.1093/jnci/89.3.227.Peer-Reviewed Original Research